Devon Miller
YOU?
Author Swipe
View article: BCL-2 Family Inhibition Enhances mTORC1/2 Inhibition in <i>PIK3CA</i> -Mutant Colorectal Cancer
BCL-2 Family Inhibition Enhances mTORC1/2 Inhibition in <i>PIK3CA</i> -Mutant Colorectal Cancer Open
Targeting PIK3CA-mutant colorectal cancers with precision medicine strategies is of great clinical interest. However, resistance to single-agent PI3K pathway inhibitors has been observed across multiple clinical trials, necessitating the i…
View article: Table S2 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Table S2 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Stock culture and feeding media.
View article: Figure S1 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Figure S1 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Dot plots corresponding to population distribution curves and graphs of individual replicates for bar graphs in Figure 4.
View article: Figure S2 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Figure S2 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Individual replicates for data shown in Figure 5B.
View article: Table S2 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Table S2 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Stock culture and feeding media.
View article: Data from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Data from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Purpose:Cancer treatment is limited by inaccurate predictors of patient-specific therapeutic response. Therefore, some patients are exposed to unnecessary side effects and delays in starting effective therapy. A clinical tool that predicts…
View article: Table S3 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Table S3 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Detailed characteristics of CRC PDOCS.
View article: Supplementary Data from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Supplementary Data from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Supplementary Methods
View article: Figure S2 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Figure S2 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Individual replicates for data shown in Figure 5B.
View article: Table S3 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Table S3 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Detailed characteristics of CRC PDOCS.
View article: Figure S3 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Figure S3 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Individual replicates for data shown in Figure 5E.
View article: Supplementary Data from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Supplementary Data from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Supplementary Methods
View article: Figure S4 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Figure S4 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
(A) Individual replicates of data shown in Figure 6A. (B) Individual replicates of data from Figure 6D.
View article: Figure S1 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Figure S1 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Dot plots corresponding to population distribution curves and graphs of individual replicates for bar graphs in Figure 4.
View article: Figure S3 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Figure S3 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Individual replicates for data shown in Figure 5E.
View article: Table S1 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Table S1 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Success rates for growing human cancers in spheroid culture
View article: Table S1 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Table S1 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Success rates for growing human cancers in spheroid culture
View article: Data from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Data from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Purpose:Cancer treatment is limited by inaccurate predictors of patient-specific therapeutic response. Therefore, some patients are exposed to unnecessary side effects and delays in starting effective therapy. A clinical tool that predicts…
View article: Figure S4 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Figure S4 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
(A) Individual replicates of data shown in Figure 6A. (B) Individual replicates of data from Figure 6D.
View article: Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy
Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy Open
Background Sarcomas are rare diagnoses but are seen with relative frequency in adolescents and young adults and thus can present in pregnancy. We sought to study the administration of anthracyclines and/or ifosfamide in pregnancy‐associate…
View article: Sequential Immune Thrombocytopenia (ITP) and Thrombotic Thrombocytopenic Purpura (TTP) in an Elderly Male Patient with Primary Sjogren’s Syndrome: When in Doubt, Use the PLASMIC Score
Sequential Immune Thrombocytopenia (ITP) and Thrombotic Thrombocytopenic Purpura (TTP) in an Elderly Male Patient with Primary Sjogren’s Syndrome: When in Doubt, Use the PLASMIC Score Open
Introduction. Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening thrombotic microangiopathy due to an acquired autoantibody to ADAMTS13 that requires a boutique treatment, urgent plasma exchange. Thus, TTP is often terme…
View article: Integrating Subclonal Response Heterogeneity to Define Cancer Organoid Therapeutic Sensitivity
Integrating Subclonal Response Heterogeneity to Define Cancer Organoid Therapeutic Sensitivity Open
Tumor heterogeneity is predicted to confer inferior clinical outcomes, however modeling heterogeneity in a manner that still represents the tumor of origin remains a formidable challenge. Sequencing technologies are limited in their abilit…
View article: Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Purpose: Cancer treatment is limited by inaccurate predictors of patient-specific therapeutic response. Therefore, some patients are exposed to unnecessary side effects and delays in starting effective therapy. A clinical tool that predict…
View article: Fisetin and 5‐fluorouracil: Effective combination for <i>PIK3CA</i>‐mutant colorectal cancer
Fisetin and 5‐fluorouracil: Effective combination for <i>PIK3CA</i>‐mutant colorectal cancer Open
The normal colon epithelium is transformed into its neoplastic counterpart through a series of genetic alterations in driver genes including activating mutations in PIK3CA . Treatment often involves surgery followed by 5‐fluorouracil (5‐FU…
View article: Heterochromatin Protein 1 Binding Protein 3 Expression as a Candidate Marker of Intrinsic 5-Fluorouracil Resistance.
Heterochromatin Protein 1 Binding Protein 3 Expression as a Candidate Marker of Intrinsic 5-Fluorouracil Resistance. Open
Using mouse models of human colorectal cancer, Hp1bp3 was identified as a candidate marker of intrinsic 5-FU resistance and may represent a potential biomarker for patient stratification or a target of clinical importance.